Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
L274785-1mg | 1mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $328.90 | |
L274785-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $523.90 | |
L274785-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $354.90 | |
L274785-25mg | 25mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,047.90 | |
L274785-50mg | 50mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,434.90 |
Group II mGlu agonist. Systemically active.
Synonyms | 191471-52-0|LY379268|LY 379268|LY-379268|(1R,4R,5S,6R)-4-Amino-2-oxabicyclo[3.1.0]hexane-4,6-dicarboxylic acid|CHEMBL275079|S96JF4J697|191471-50-8|LY-379,268|(1S,2R,5R,6R)-2-amino-4-oxabicyclo[3.1.0]hexane-2,6-dicarboxylic acid|2-Oxabicyclo[3.1.0]hexane-4 |
---|---|
Specifications & Purity | Moligand™, ≥99% |
Biochemical and Physiological Mechanisms | Highly potent and systemically active mGlu 2 and mGlu 3 agonist. EC 50 values are 2.69 and 4.48 nM for hmGlu 2 and hmGlu 3 , respectively and displays >80-fold selectivity over group I and group III receptors. Effective in several animal models of stroke, |
Storage Temp | Store at 2-8°C,Desiccated |
Shipped In | Wet ice |
Grade | Moligand™ |
Action Type | AGONIST |
Mechanism of action | Agonist of mGlu 2 receptor;Agonist of mGlu 3 receptor;Agonist of mGlu 6 receptor |
Note | Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour. Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details. |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IUPAC Name | (1R,4R,5S,6R)-4-amino-2-oxabicyclo[3.1.0]hexane-4,6-dicarboxylic acid |
---|---|
INCHI | InChI=1S/C7H9NO5/c8-7(6(11)12)1-13-4-2(3(4)7)5(9)10/h2-4H,1,8H2,(H,9,10)(H,11,12)/t2-,3-,4+,7+/m1/s1 |
InChi Key | YASVRZWVUGJELU-MDASVERJSA-N |
Canonical SMILES | C1C(C2C(C2O1)C(=O)O)(C(=O)O)N |
Isomeric SMILES | C1[C@]([C@@H]2[C@H]([C@@H]2O1)C(=O)O)(C(=O)O)N |
PubChem CID | 10197984 |
Molecular Weight | 187.15 |
PubChem CID | 10197984 |
---|---|
ChEMBL Ligand | CHEMBL275079 |
BindingDB Ligand | 50089890 |
Wikipedia | LY-379,268 |
CAS Registry No. | 191471-52-0 |
GPCRdb Ligand | LY379268 |
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
A2422002 | Certificate of Analysis | Dec 19, 2023 | L274785 |
A2422003 | Certificate of Analysis | Dec 19, 2023 | L274785 |
A2422004 | Certificate of Analysis | Dec 19, 2023 | L274785 |
A2422005 | Certificate of Analysis | Dec 19, 2023 | L274785 |
A2422006 | Certificate of Analysis | Dec 19, 2023 | L274785 |
A2422007 | Certificate of Analysis | Dec 19, 2023 | L274785 |
A2422008 | Certificate of Analysis | Dec 19, 2023 | L274785 |
A2422009 | Certificate of Analysis | Dec 19, 2023 | L274785 |
A2422010 | Certificate of Analysis | Dec 19, 2023 | L274785 |
A2422011 | Certificate of Analysis | Dec 19, 2023 | L274785 |
Solubility | Soluble in water to 25 mM (with heating) |
---|
1. Yin S, Noetzel MJ, Johnson KA, Zamorano R, Jalan-Sakrikar N, Gregory KJ, Conn PJ, Niswender CM. (2014) Selective actions of novel allosteric modulators reveal functional heteromers of metabotropic glutamate receptors in the CNS.. J Neurosci, 34 (1): (79-94). [PMID:24381270] |
2. Liu J et al.. (2021) Abnormal Glu/mGluR2/3/PI3K pathway in the hippocampal neurovascular unit leads to diabetes-related depression.. Neural Regen Res, 16 (4): (727-733). [PMID:33063735] |
3. Bragina L et al.. (2015) Differential expression of metabotropic glutamate and GABA receptors at neocortical glutamatergic and GABAergic axon terminals.. Front Cell Neurosci, 9 (345). [PMID:26388733] |
4. Klakotskaia D et al.. (2013) Effects of group II and III metabotropic glutamate receptor ligands on conditioned taste aversion learning.. Behav Brain Res, 253 (9-16). [PMID:23827202] |
5. Špirková A et al.. (2022) Glutamate can act as a signaling molecule in mouse preimplantation embryos†.. Biol Reprod, 107 (4): (916-927). [PMID:35746896] |
6. Gosnell HB et al.. (2011) mGluR8 modulates excitatory transmission in the bed nucleus of the stria terminalis in a stress-dependent manner.. Neuropsychopharmacology, 36 (8): (1599-607). [PMID:21451497] |
7. Rylander D et al.. (2009) Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling.. J Pharmacol Exp Ther, 330 (227-35). [PMID:19357321] |
8. Cuccurazzu B et al.. (2013) Upregulation of mGlu2 Receptors via NF-?B p65 Acetylation Is Involved in the Proneurogenic and Antidepressant Effects of Acetyl-L-Carnitine.. Neuropsychopharmacology, 38 (11): (2220-30). [PMID:23670591] |